

*Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**INNOCARE**

諾誠健華

**InnoCare Pharma Limited**

**諾誠健華醫藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 9969)**

## **INSIDE INFORMATION ANNOUNCEMENT**

### **DETERMINATION OF OFFERING SIZE AND OFFERING PRICE FOR RMB SHARE ISSUE**

This announcement is made by InnoCare Pharma Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the Company’s announcements dated 11 March 2021, 26 May 2021, 13 September 2021, 13 April 2022, 1 June 2022, 3 August 2022, 5 August 2022, 22 August 2022 and 1 September 2022 and the Company’s circulars dated 3 June 2021, 18 May 2022 and supplemental circular dated 6 June 2022 (the “**Circulars**”) in relation to, among others, the RMB Share Issue. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circulars.

The Board is pleased to announce that, following the completion of the preliminary price consultations among inquiry targets on 6 September 2022, the Company will issue 264,648,217 RMB Shares at the issue price of RMB11.03 per RMB Share, representing approximately 15.00% of the sum of the total number of issued Shares of the Company as of 1 September 2022 and the number of RMB Shares to be issued and placed under this RMB Share Issue. The issue price was negotiated and determined by the Company and the joint lead underwriters based on the results of the preliminary consultations, comprehensively evaluating the reasonable investment value of the Company, the valuation level of the secondary market of comparable companies and the valuation level of the secondary market of the industry and thoroughly taking into account the effective subscription multiple of offline investors, market conditions, needs for the proceeds, underwriting risks as well as other factors.

For the relevant terms of the RMB Share Issue, please refer to the full text of the Issue Announcement of InnoCare Pharma Limited for the Initial Public Offering and Listing of Stocks on the STAR Market (《諾誠健華醫藥有限公司首次公開發行股票並在科創板上市發行公告》) published in Chinese on the website of the SSE ([www.sse.com.cn](http://www.sse.com.cn)) on 8 September 2022.

The consummation of the RMB Share Issue is subject to, among other things, market conditions and customary closing conditions related to the RMB Share Issue. Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company. Further announcement(s) will be made to disclose any material updates and developments in respect of the RMB Share Issue in accordance with the Listing Rules and other applicable laws and regulations as and when appropriate. This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

By order of the Board  
**InnoCare Pharma Limited**  
**Dr. Jisong Cui**  
*Chairperson and Executive Director*

Hong Kong, 8 September 2022

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Shan Fu, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Dr. Zemin Zhang, Ms. Lan Hu and Dr. Kaixian Chen as independent non-executive Directors.*